{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T04:38:16Z","timestamp":1783485496287,"version":"3.55.0"},"reference-count":124,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","jaad.org","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.jaad.2018.08.061","type":"journal-article","created":{"date-parts":[[2018,10,10]],"date-time":"2018-10-10T04:06:26Z","timestamp":1539144386000},"page":"1509-1521","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":58,"title":["Androgens in women"],"prefix":"10.1016","volume":"80","author":[{"given":"Sarah","family":"Azarchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Bienenfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Lo Sicco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shari","family":"Marchbein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry","family":"Shapiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arielle R.","family":"Nagler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2018.08.061_bib1","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/0010-7824(96)00006-6","article-title":"Changes in androgens during treatment with four low-dose contraceptives","volume":"53","author":"Coenen","year":"1996","journal-title":"Contraception"},{"key":"10.1016\/j.jaad.2018.08.061_bib2","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.jaad.2015.12.037","article-title":"Guidelines of care for the management of acne vulgaris","volume":"74","author":"Zaenglein","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2018.08.061_bib3","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1210\/edrv.21.4.0404","article-title":"Role of hormones in pilosebaceous unit development","volume":"21","author":"Deplewski","year":"2000","journal-title":"Endocr Rev"},{"issue":"suppl 1","key":"10.1016\/j.jaad.2018.08.061_bib4","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/bjd.13681","article-title":"Is hormonal treatment still an option in acne today?","volume":"172","author":"Bettoli","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2018.08.061_bib5","doi-asserted-by":"crossref","first-page":"859.e1","DOI":"10.1016\/j.jaad.2014.05.009","article-title":"Polycystic ovary syndrome: a review for dermatologists: part II. Treatment","volume":"71","author":"Buzney","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"3 suppl","key":"10.1016\/j.jaad.2018.08.061_bib6","doi-asserted-by":"crossref","first-page":"23S","DOI":"10.1016\/S0010-7824(98)00079-1","article-title":"Uniqueness of oral contraceptive progestins","volume":"58","author":"Carr","year":"1998","journal-title":"Contraception"},{"key":"10.1016\/j.jaad.2018.08.061_bib7","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1177\/106002809502907-817","article-title":"Desogestrel, norgestimate, and gestodene: the newer progestins","volume":"29","author":"Kaplan","year":"1995","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jaad.2018.08.061_bib8","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jaad.2017.09.078","article-title":"Practical management of acne for clinicians: an international consensus from the Global Alliance to Improve Outcomes in Acne","volume":"78","author":"Thiboutot","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2018.08.061_bib9","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.fertnstert.2005.07.1311","article-title":"Efficacy of a new oral contraceptive containing drospirenone and ethinyl estradiol in the long-term treatment of hirsutism","volume":"85","author":"Batukan","year":"2006","journal-title":"Fertil Steril"},{"key":"10.1016\/j.jaad.2018.08.061_bib10","first-page":"975","article-title":"Evolution of progestins. Focus on the novel progestin drospirenone","volume":"47","author":"Thorneycroft","year":"2002","journal-title":"J Reprod Med"},{"key":"10.1016\/j.jaad.2018.08.061_bib11","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/0022-4731(88)90295-6","article-title":"Androgenic activity of synthetic progestins and spironolactone in androgen-sensitive mouse mammary carcinoma (Shionogi) cells in culture","volume":"31","author":"Luthy","year":"1988","journal-title":"J Steroid Biochem"},{"key":"10.1016\/j.jaad.2018.08.061_bib12","first-page":"83","article-title":"Combined oral contraceptives for the treatment of acne: a practical guide","volume":"90","author":"Arrington","year":"2012","journal-title":"Cutis"},{"key":"10.1016\/j.jaad.2018.08.061_bib13","first-page":"CD010813","article-title":"Combined oral contraceptives: venous thrombosis","author":"de Bastos","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jaad.2018.08.061_bib14","first-page":"CD011054","article-title":"Combined oral contraceptives: the risk of myocardial infarction and ischemic stroke","author":"Roach","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jaad.2018.08.061_bib15","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1056\/NEJMe1204769","article-title":"Hormonal contraceptives and arterial thrombosis\u2013not risk-free but safe enough","volume":"366","author":"Petitti","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2018.08.061_bib16","first-page":"93","article-title":"The use of hormonal contraception in women with coexisting medical conditions. Number 18, July 2000","volume":"75","year":"2001","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.jaad.2018.08.061_bib17","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1158\/1055-9965.EPI-13-0298","article-title":"Oral contraceptive use and risk of breast, cervical, colorectal, and endometrial cancers: a systematic review","volume":"22","author":"Gierisch","year":"2013","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.jaad.2018.08.061_bib18","first-page":"1","article-title":"Oral contraceptive use for the primary prevention of ovarian cancer","author":"Havrilesky","year":"2013","journal-title":"Evid Rep Technol Assess (Full Rep)"},{"key":"10.1016\/j.jaad.2018.08.061_bib19","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0015-0282(16)59346-7","article-title":"The endocrine effects of spironolactone used as an antiandrogen","volume":"48","author":"Young","year":"1987","journal-title":"Fertil Steril"},{"key":"10.1016\/j.jaad.2018.08.061_bib20","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1139\/o79-131","article-title":"Interaction of spironolactone with rat skin androgen receptor","volume":"57","author":"Boisselle","year":"1979","journal-title":"Can J Biochem"},{"key":"10.1016\/j.jaad.2018.08.061_bib21","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1210\/endo-94-6-1628","article-title":"Spironolactone and testicular cytochrome P-450: decreased testosterone formation in several species and changes in hepatic drug metabolism","volume":"94","author":"Menard","year":"1974","journal-title":"Endocrinology"},{"key":"10.1016\/j.jaad.2018.08.061_bib22","doi-asserted-by":"crossref","first-page":"630","DOI":"10.7326\/0003-4819-85-5-630","article-title":"Spironolactone and endocrine dysfunction","volume":"85","year":"1976","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaad.2018.08.061_bib23","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1001\/jamadermatol.2015.34","article-title":"Low usefulness of potassium monitoring among healthy young women taking spironolactone for acne","volume":"151","author":"Plovanich","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2018.08.061_bib24","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaad.2007.09.024","article-title":"Efficacy and tolerance of acne treatment using both spironolactone and a combined contraceptive containing drospirenone","volume":"58","author":"Krunic","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2018.08.061_bib25","doi-asserted-by":"crossref","first-page":"e4447","DOI":"10.1136\/bmj.e4447","article-title":"Spironolactone and risk of incident breast cancer in women older than 55 years: retrospective, matched cohort study","volume":"345","author":"Mackenzie","year":"2012","journal-title":"BMJ"},{"key":"10.1016\/j.jaad.2018.08.061_bib26","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.canep.2013.10.004","article-title":"Spironolactone use and the risk of breast and gynecologic cancers","volume":"37","author":"Biggar","year":"2013","journal-title":"Cancer Epidemiol"},{"key":"10.1016\/j.jaad.2018.08.061_bib27","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.fertnstert.2012.06.018","article-title":"Hepatotoxicity with low- and ultralow-dose flutamide: a surveillance study on 203 hyperandrogenic young females","volume":"98","author":"Bruni","year":"2012","journal-title":"Fertil Steril"},{"key":"10.1016\/j.jaad.2018.08.061_bib28","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s00404-008-0719-z","article-title":"The risk of hepatotoxicity during long-term and low-dose flutamide treatment in hirsutism","volume":"279","author":"Dikensoy","year":"2009","journal-title":"Arch Gynecol Obstet"},{"key":"10.1016\/j.jaad.2018.08.061_bib29","doi-asserted-by":"crossref","first-page":"860","DOI":"10.7326\/0003-4819-118-11-199306010-00006","article-title":"Fatal and nonfatal hepatotoxicity associated with flutamide","volume":"118","author":"Wysowski","year":"1993","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaad.2018.08.061_bib30","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1021\/tx7001349","article-title":"Comparison of the cytotoxicity of the nitroaromatic drug flutamide to its cyano analogue in the\u00a0hepatocyte cell line TAMH: evidence for complex I inhibition and mitochondrial dysfunction using toxicogenomic screening","volume":"20","author":"Coe","year":"2007","journal-title":"Chem Res Toxicol"},{"key":"10.1016\/j.jaad.2018.08.061_bib31","first-page":"69","article-title":"Flutamide-induced hepatotoxicity: ethical and scientific issues","volume":"21","author":"Giorgetti","year":"2017","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.jaad.2018.08.061_bib32","series-title":"Fluatmide [package insert]","year":"2016"},{"key":"10.1016\/j.jaad.2018.08.061_bib33","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1349-7006.2007.00656.x","article-title":"Novel 5 alpha-steroid reductase (SRD5A3, type-3) is overexpressed in hormone-refractory prostate cancer","volume":"99","author":"Uemura","year":"2008","journal-title":"Cancer Sci"},{"key":"10.1016\/j.jaad.2018.08.061_bib34","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1515\/HMBCI.2010.035","article-title":"Human type 3 5alpha-reductase is expressed in peripheral tissues at higher levels than types 1 and 2 and its activity is potently inhibited by finasteride and dutasteride","volume":"2","author":"Yamana","year":"2010","journal-title":"Horm Mol Biol Clin Investig"},{"key":"10.1016\/j.jaad.2018.08.061_bib35","series-title":"Propecia (finasteride) [package insert]","year":"2010"},{"key":"10.1016\/j.jaad.2018.08.061_bib36","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s40257-014-0077-5","article-title":"Androgenetic alopecia: an evidence-based treatment update","volume":"15","author":"Varothai","year":"2014","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaad.2018.08.061_bib37","first-page":"56","article-title":"Adverse effects and safety of 5-alpha reductase inhibitors (finasteride, dutasteride): a systematic review","volume":"9","author":"Hirshburg","year":"2016","journal-title":"J Clin Aesthet Dermatol"},{"key":"10.1016\/j.jaad.2018.08.061_bib38","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1111\/j.1743-6109.2010.02157.x","article-title":"Adverse side effects of 5alpha-reductase inhibitors therapy: persistent diminished libido and erectile dysfunction and depression in a subset of patients","volume":"8","author":"Traish","year":"2011","journal-title":"J Sex Med"},{"key":"10.1016\/j.jaad.2018.08.061_bib39","doi-asserted-by":"crossref","first-page":"102","DOI":"10.4103\/0974-2077.69022","article-title":"Finasteride and male breast cancer: does the MHRA report show a link?","volume":"3","author":"Shenoy","year":"2010","journal-title":"J Cutan Aesthet Surg"},{"key":"10.1016\/j.jaad.2018.08.061_bib40","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1007\/s40265-016-0629-5","article-title":"Androgenetic alopecia: an update of treatment options","volume":"76","author":"Kelly","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.jaad.2018.08.061_bib41","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial","volume":"288","author":"Rossouw","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.jaad.2018.08.061_bib42","first-page":"2","article-title":"The effect of 2 combined oral Contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea","volume":"69","author":"van Vloten","year":"2002","journal-title":"Cutis"},{"key":"10.1016\/j.jaad.2018.08.061_bib43","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/S0015-0282(00)01764-7","article-title":"Comparison of Diane 35 and Diane 35 plus finasteride in the treatment of hirsutism","volume":"75","author":"Sahin","year":"2001","journal-title":"Fertil Steril"},{"key":"10.1016\/j.jaad.2018.08.061_bib44","first-page":"109","article-title":"Treatment of hirsutism in polycystic ovarian syndrome with Diane, 50 mcg ethinyl estradiol and 2 mg cyproterone acetate","volume":"9","author":"Saeed","year":"1993","journal-title":"Specialist"},{"key":"10.1016\/j.jaad.2018.08.061_bib45","first-page":"189","article-title":"Female pattern hair loss: current treatment concepts","volume":"2","author":"Dinh","year":"2007","journal-title":"Clin Interv Aging"},{"key":"10.1016\/j.jaad.2018.08.061_bib46","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.clindermatol.2016.10.009","article-title":"Hormonal therapies for acne","volume":"35","author":"Barros","year":"2017","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.jaad.2018.08.061_bib47","first-page":"143","article-title":"A combined oral contraceptive containing 3-mg drospirenone\/20-microg ethinyl estradiol in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled study evaluating lesion counts and participant self-assessment","volume":"82","author":"Lucky","year":"2008","journal-title":"Cutis"},{"key":"10.1016\/j.jaad.2018.08.061_bib48","first-page":"837","article-title":"A randomized controlled trial of a low-dose combined oral contraceptive containing 3 mg drospirenone plus 20 microg ethinylestradiol in the treatment of acne vulgaris: lesion counts, investigator ratings and subject self-assessment","volume":"8","author":"Maloney","year":"2009","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaad.2018.08.061_bib49","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.contraception.2007.11.003","article-title":"Efficacy and safety of 3 mg drospirenone\/20 mcg ethinylestradiol oral contraceptive administered in 24\/4 regimen in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled trial","volume":"77","author":"Koltun","year":"2008","journal-title":"Contraception"},{"key":"10.1016\/j.jaad.2018.08.061_bib50","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ejogrb.2010.12.027","article-title":"Treatment of moderate acne vulgaris using a combined oral contraceptive containing ethinylestradiol 20 mug plus drospirenone 3mg administered in a 24\/4 regimen: a pooled analysis","volume":"155","author":"Koltun","year":"2011","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.jaad.2018.08.061_bib51","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.contraception.2009.02.016","article-title":"Efficacy of an oral contraceptive containing EE 0.03 mg and CMA 2 mg (Belara) in moderate acne resolution: a randomized, double-blind, placebo-controlled phase III trial","volume":"80","author":"Plewig","year":"2009","journal-title":"Contraception"},{"key":"10.1016\/j.jaad.2018.08.061_bib52","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S0015-0282(01)01938-0","article-title":"A randomized, controlled trial of a low-dose contraceptive containing 20 microg of ethinyl estradiol and 100 microg of levonorgestrel for acne treatment","volume":"76","author":"Thiboutot","year":"2001","journal-title":"Fertil Steril"},{"key":"10.1016\/j.jaad.2018.08.061_bib53","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1067\/mjd.2002.122192","article-title":"Efficacy of a low-dose oral contraceptive containing 20 microg of ethinyl estradiol and 100 microg of levonorgestrel for the treatment of moderate acne: a randomized, placebo-controlled trial","volume":"47","author":"Leyden","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2018.08.061_bib54","first-page":"633","article-title":"A single-center, randomized double-blind, parallel-group study to examine the safety and efficacy of 3mg drospirenone\/0.02 mg ethinyl estradiol compared with placebo in the treatment of moderate truncal acne vulgaris","volume":"12","author":"Palli","year":"2013","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaad.2018.08.061_bib55","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.clindermatol.2004.03.010","article-title":"Acne: hormonal concepts and therapy","volume":"22","author":"Thiboutot","year":"2004","journal-title":"Clin Dermatol"},{"issue":"7","key":"10.1016\/j.jaad.2018.08.061_bib56","first-page":"CD004425","article-title":"Combined oral contraceptive pills for treatment of acne","author":"Arowojolu","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jaad.2018.08.061_bib57","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.jaad.2014.03.051","article-title":"Meta-analysis comparing efficacy of antibiotics versus oral contraceptives in acne vulgaris","volume":"71","author":"Koo","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2018.08.061_bib58","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1067\/mjd.2002.120448","article-title":"Oral contraceptive efficacy and antibiotic interaction: a myth debunked","volume":"46","author":"Archer","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2018.08.061_bib59","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/j.1365-2133.1986.tb05722.x","article-title":"Oral spironolactone: an effective treatment for acne vulgaris in women","volume":"115","author":"Muhlemann","year":"1986","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2018.08.061_bib60","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1365-2133.1984.tb04045.x","article-title":"Oral spironolactone improves acne vulgaris and reduces sebum excretion","volume":"111","author":"Goodfellow","year":"1984","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2018.08.061_bib61","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s00266-006-0081-0","article-title":"Anti-androgenic therapy using oral spironolactone for acne vulgaris in Asians","volume":"30","author":"Sato","year":"2006","journal-title":"Aesthetic Plast Surg"},{"key":"10.1016\/j.jaad.2018.08.061_bib62","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/j.1365-2133.1985.tb02305.x","article-title":"Oral spironolactone therapy for female patients with acne, hirsutism or androgenic alopecia","volume":"112","author":"Burke","year":"1985","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2018.08.061_bib63","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1067\/mjd.2000.105557","article-title":"Low-dose adjunctive spironolactone in the treatment of acne in women: a retrospective analysis of 85 consecutively treated patients","volume":"43","author":"Shaw","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2018.08.061_bib64","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.1468-3083.2005.01072.x","article-title":"Effects and side-effects of spironolactone therapy in women with acne","volume":"19","author":"Yemisci","year":"2005","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"10.1016\/j.jaad.2018.08.061_bib65","first-page":"CD000194","article-title":"Spironolactone versus placebo or in combination with steroids for hirsutism and\/or acne","author":"Brown","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jaad.2018.08.061_bib66","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s40257-016-0245-x","article-title":"Oral spironolactone for acne vulgaris in adult females: a hybrid systematic review","volume":"18","author":"Layton","year":"2017","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaad.2018.08.061_bib67","doi-asserted-by":"crossref","first-page":"120","DOI":"10.4158\/EP.7.2.120","article-title":"American Association of Clinical Endocrinologists medical guidelines for the clinical practice for the diagnosis and treatment of hyperandrogenic disorders","volume":"7","author":"Goodman","year":"2001","journal-title":"Endocr Pract"},{"key":"10.1016\/j.jaad.2018.08.061_bib68","first-page":"423","article-title":"Low dose flutamide in the treatment of acne vulgaris in women with or without oligomenorrhea or amenorrhea","volume":"22","author":"Wang","year":"1999","journal-title":"Changgeng Yi Xue Za Zhi"},{"key":"10.1016\/j.jaad.2018.08.061_bib69","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1046\/j.1365-2265.2002.01594.x","article-title":"A comparison of the relative efficacy of antiandrogens for the treatment of acne in hyperandrogenic women","volume":"57","author":"Carmina","year":"2002","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.jaad.2018.08.061_bib70","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2147\/CCID.S20543","article-title":"Flutamide versus a cyproterone acetate-ethinyl estradiol combination in moderate acne: a pilot randomized clinical trial","volume":"4","author":"Adalatkhah","year":"2011","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"10.1016\/j.jaad.2018.08.061_bib71","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0015-0282(16)57727-9","article-title":"Clinical and endocrine effects of finasteride, a 5 alpha-reductase inhibitor, in women with idiopathic hirsutism","volume":"64","author":"Ciotta","year":"1995","journal-title":"Fertil Steril"},{"key":"10.1016\/j.jaad.2018.08.061_bib72","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1080\/gye.17.1.57.63","article-title":"The benefits of finasteride for hirsute women with polycystic ovary syndrome or idiopathic hirsutism","volume":"17","author":"Lakryc","year":"2003","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.jaad.2018.08.061_bib73","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4103\/0019-5154.60342","article-title":"Hirsutism: evaluation and treatment","volume":"55","author":"Sachdeva","year":"2010","journal-title":"Indian J Dermatol"},{"key":"10.1016\/j.jaad.2018.08.061_bib74","first-page":"41","article-title":"Non-contraceptive benefits of oral hormonal contraceptives","volume":"11","author":"Schindler","year":"2013","journal-title":"Int J Endocrinol Metab"},{"key":"10.1016\/j.jaad.2018.08.061_bib75","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1111\/j.1365-2265.2007.03105.x","article-title":"A systematic review of commonly used medical treatments for hirsutism in women","volume":"68","author":"Koulouri","year":"2008","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.jaad.2018.08.061_bib76","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ejogrb.2003.09.030","article-title":"Antiandrogenic progestins for treatment of signs of androgenisation and hormonal contraception","volume":"112","author":"Schindler","year":"2004","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.jaad.2018.08.061_bib77","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1210\/jc.2007-2437","article-title":"Evaluation and treatment of hirsutism in premenopausal women: an endocrine society clinical practice guideline","volume":"93","author":"Martin","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jaad.2018.08.061_bib78","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/S0015-0282(16)54291-5","article-title":"Long-term treatment of hirsutism: desogestrel compared with cyproterone acetate in oral contraceptives","volume":"55","author":"Porcile","year":"1991","journal-title":"Fertil Steril"},{"key":"10.1016\/j.jaad.2018.08.061_bib79","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S0015-0282(98)00486-5","article-title":"Treatment of hirsutism: comparisons between different antiandrogens with central and peripheral effects","volume":"71","author":"Fruzzetti","year":"1999","journal-title":"Fertil Steril"},{"key":"10.1016\/j.jaad.2018.08.061_bib80","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1046\/j.1365-2265.2000.00982.x","article-title":"Spironolactone as a single agent for long-term therapy of hirsute patients","volume":"52","author":"Spritzer","year":"2000","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.jaad.2018.08.061_bib81","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1210\/jc.2017-02052","article-title":"Treatment options for hirsutism: a systematic review and network meta-analysis","volume":"103","author":"Barrionuevo","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"suppl 1","key":"10.1016\/j.jaad.2018.08.061_bib82","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.4103\/2230-8210.119511","article-title":"Management of hirsutism","volume":"17","author":"Agrawal","year":"2013","journal-title":"Indian J Endocrinol Metab"},{"key":"10.1016\/j.jaad.2018.08.061_bib83","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/j.1365-2265.1995.tb02922.x","article-title":"Clinical efficacy and safety of low-dose flutamide alone and combined with an oral contraceptive for the treatment of idiopathic hirsutism","volume":"43","author":"Dodin","year":"1995","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.jaad.2018.08.061_bib84","first-page":"89","article-title":"Comparison of spironolactone, flutamide, and finasteride efficacy in the treatment of hirsutism: a randomized, double blind, placebo-controlled trial","volume":"85","author":"Moghetti","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.jaad.2018.08.061_bib85","first-page":"CD007628","article-title":"Interventions for female pattern hair loss","author":"van Zuuren","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jaad.2018.08.061_bib86","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/S0015-0282(02)04294-2","article-title":"Comparison of spironolactone and spironolactone plus finasteride in the treatment of hirsutism","volume":"78","author":"Unluhizarci","year":"2002","journal-title":"Fertil Steril"},{"key":"10.1016\/j.jaad.2018.08.061_bib87","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S0015-0282(16)48373-1","article-title":"The effects of two doses of spironolactone on serum androgens and anagen hair in hirsute women","volume":"43","author":"Lobo","year":"1985","journal-title":"Fertil Steril"},{"key":"10.1016\/j.jaad.2018.08.061_bib88","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3949\/ccjm.57.3.285","article-title":"Use of spironolactone in treatment of hirsutism","volume":"57","author":"Cumming","year":"1990","journal-title":"Cleve Clin J Med"},{"key":"10.1016\/j.jaad.2018.08.061_bib89","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/j.1529-8019.2008.00219.x","article-title":"The clinical evaluation of hirsutism","volume":"21","author":"Somani","year":"2008","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jaad.2018.08.061_bib90","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1007\/BF03350800","article-title":"Effect of finasteride in idiopathic hirsutism","volume":"21","author":"Faloia","year":"1998","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.jaad.2018.08.061_bib91","first-page":"233","article-title":"A prospective randomized\u00a0trial comparing finasteride to spironolactone in the treatment of hirsute women","volume":"80","author":"Wong","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jaad.2018.08.061_bib92","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/S0015-0282(97)00371-3","article-title":"Comparison of finasteride versus spironolactone in the treatment of idiopathic hirsutism","volume":"68","author":"Erenus","year":"1997","journal-title":"Fertil Steril"},{"key":"10.1016\/j.jaad.2018.08.061_bib93","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1530\/eje.0.1470467","article-title":"Comparison of high-dose finasteride (5 mg\/day) versus low-dose finasteride (2.5 mg\/day) in the treatment of hirsutism","volume":"147","author":"Bayram","year":"2002","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.jaad.2018.08.061_bib94","first-page":"19","article-title":"Finasteride for hirsutism: a dose finding study","volume":"19","author":"Al-Khawajah","year":"1998","journal-title":"Saudi Med J"},{"key":"10.1016\/j.jaad.2018.08.061_bib95","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/bjd.14486","article-title":"Interventions for hirsutism excluding laser and photoepilation therapy alone: abridged Cochrane systematic review including GRADE assessments","volume":"175","author":"van Zuuren","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2018.08.061_bib96","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ijgo.2004.06.003","article-title":"Finasteride versus cyproterone acetate-estrogen regimens in the treatment of hirsutism","volume":"87","author":"Beigi","year":"2004","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.jaad.2018.08.061_bib97","doi-asserted-by":"crossref","first-page":"3970","DOI":"10.1210\/jc.2005-2250","article-title":"Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study","volume":"91","author":"Gambineri","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jaad.2018.08.061_bib98","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/S0015-0282(00)00470-2","article-title":"A prospective, randomized trial comparing flutamide (250 mg\/d) and finasteride (5 mg\/d) in the treatment of hirsutism","volume":"73","author":"Muderris","year":"2000","journal-title":"Fertil Steril"},{"key":"10.1016\/j.jaad.2018.08.061_bib99","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1530\/eje.0.1410361","article-title":"Comparison of finasteride versus flutamide in the treatment of hirsutism","volume":"141","author":"Falsetti","year":"1999","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.jaad.2018.08.061_bib100","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1310\/hpj4906-517","article-title":"Flutamide: hirsutism in women","volume":"49","author":"Generali","year":"2014","journal-title":"Hosp Pharm"},{"key":"10.1016\/j.jaad.2018.08.061_bib101","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1093\/humupd\/dmr042","article-title":"Epidemiology, diagnosis and management of hirsutism: a consensus\u00a0statement by the Androgen Excess and Polycystic Ovary Syndrome Society","volume":"18","author":"Escobar-Morreale","year":"2012","journal-title":"Hum Reprod Update"},{"key":"10.1016\/j.jaad.2018.08.061_bib102","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1210\/jcem.84.4.5591","article-title":"A prospective randomized trial comparing low dose flutamide, finasteride, ketoconazole, and cyproterone acetate-estrogen regimens in the treatment of hirsutism","volume":"84","author":"Venturoli","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jaad.2018.08.061_bib103","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1080\/gye.16.1.63.66","article-title":"New alternative treatment in hirsutism: bicalutamide 25 mg\/day","volume":"16","author":"Muderris","year":"2002","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.jaad.2018.08.061_bib104","doi-asserted-by":"crossref","first-page":"268","DOI":"10.2143\/ACB.3267","article-title":"Update on idiopathic hirsutism: diagnosis and treatment","volume":"68","author":"Erem","year":"2013","journal-title":"Acta Clin Belg"},{"key":"10.1016\/j.jaad.2018.08.061_bib105","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1529-8019.2008.00215.x","article-title":"Medical treatment of hirsutism","volume":"21","author":"Blume-Peytavi","year":"2008","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jaad.2018.08.061_bib106","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5070\/D33B81S01S","article-title":"A review of hormonal therapy for female pattern (androgenic) alopecia","volume":"14","author":"Scheinfeld","year":"2008","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.jaad.2018.08.061_bib107","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.jaad.2015.06.063","article-title":"Demographics of women with female pattern hair loss and the effectiveness of spironolactone therapy","volume":"73","author":"Famenini","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2018.08.061_bib108","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/j.1365-2133.2005.06218.x","article-title":"Treatment of female pattern hair loss with oral antiandrogens","volume":"152","author":"Sinclair","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2018.08.061_bib109","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1468-3083.1999.tb01030.x","article-title":"Management of androgenetic alopecia","volume":"12","author":"Tosti","year":"1999","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2018.08.061_bib110","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1056\/NEJMcp072110","article-title":"Clinical practice. Hair loss in women","volume":"357","author":"Shapiro","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2018.08.061_bib111","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.det.2010.03.011","article-title":"Innovative use of spironolactone as an antiandrogen in the treatment of female pattern hair loss","volume":"28","author":"Rathnayake","year":"2010","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.jaad.2018.08.061_bib112","first-page":"5","article-title":"Androgenetic alopecia and current methods of treatment","volume":"14","author":"Bienova","year":"2005","journal-title":"Acta Dermatovenerol Alp Pannonica Adriat"},{"key":"10.1016\/j.jaad.2018.08.061_bib113","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ijwd.2017.01.001","article-title":"Hormonal therapy in female pattern hair loss","volume":"3","author":"Brough","year":"2017","journal-title":"Int J Womens Dermatol"},{"key":"10.1016\/j.jaad.2018.08.061_bib114","doi-asserted-by":"crossref","first-page":"128","DOI":"10.4103\/0378-6323.177432","article-title":"Guidelines on the use of finasteride in androgenetic alopecia","volume":"82","author":"Mysore","year":"2016","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1016\/j.jaad.2018.08.061_bib115","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1055\/s-0028-1102905","article-title":"Understanding and management of female pattern alopecia","volume":"24","author":"Leavitt","year":"2008","journal-title":"Facial Plast Surg"},{"key":"10.1016\/j.jaad.2018.08.061_bib116","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.1468-3083.2010.03758.x","article-title":"5 mg\/day finasteride treatment for normoandrogenic Asian women with female\u00a0pattern hair loss","volume":"25","author":"Yeon","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2018.08.061_bib117","doi-asserted-by":"crossref","first-page":"22","DOI":"10.4103\/0974-7753.114709","article-title":"Finasteride 5 mg\/day Treatment of Patterned Hair Loss in Normo-androgenetic Postmenopausal Women","volume":"5","author":"Oliveira-Soares","year":"2013","journal-title":"Int J Trichology"},{"key":"10.1016\/j.jaad.2018.08.061_bib118","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1067\/mjd.2000.107953","article-title":"Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia","volume":"43","author":"Price","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2018.08.061_bib119","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/sj.jidsp.5640230","article-title":"Measuring reversal of hair miniaturization in androgenetic alopecia by follicular counts in horizontal sections of serial scalp biopsies: results of finasteride 1 mg treatment of men and postmenopausal women","volume":"4","author":"Whiting","year":"1999","journal-title":"J Investig Dermatol Symp Proc"},{"key":"10.1016\/j.jaad.2018.08.061_bib120","doi-asserted-by":"crossref","first-page":"47","DOI":"10.4103\/0378-6323.188652","article-title":"Superiority of dutasteride over finasteride in hair regrowth and reversal of miniaturization in men with androgenetic alopecia: a randomized controlled open-label, evaluator-blinded study","volume":"83","author":"Shanshanwal","year":"2017","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1016\/j.jaad.2018.08.061_bib121","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jaad.2013.10.049","article-title":"A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia","volume":"70","author":"Gubelin Harcha","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2018.08.061_bib122","doi-asserted-by":"crossref","first-page":"521","DOI":"10.4103\/0378-6323.144162","article-title":"The effectiveness of finasteride and dutasteride used for 3 years in women with androgenetic alopecia","volume":"80","author":"Boersma","year":"2014","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1016\/j.jaad.2018.08.061_bib123","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1345\/aph.1P600","article-title":"Prospective cohort study\u00a0on the effects and tolerability of flutamide in patients with female pattern hair loss","volume":"45","author":"Paradisi","year":"2011","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jaad.2018.08.061_bib124","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0015-0282(02)04551-X","article-title":"Treatment of hyperandrogenic alopecia in women","volume":"79","author":"Carmina","year":"2003","journal-title":"Fertil Steril"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962218326732?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962218326732?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T05:47:02Z","timestamp":1720676822000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962218326732"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":124,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["S0190962218326732"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2018.08.061","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Androgens in women","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2018.08.061","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier on behalf of the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}